Stocktoria
Adagene Inc. ADAG
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-09
Chart by TradingView
4/9
Piotroski F — financial health
-9.75
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $7.7M | $103,204 | $18.1M | $9.3M | $10.2M |
| Operating income | -$21.4M | -$36.0M | -$23.7M | -$83.9M | -$72.4M |
| Net income | -$17.6M | -$33.4M | -$18.9M | -$80.0M | -$73.2M |
| Operating cash flow | -$15.7M | -$29.7M | -$28.5M | -$48.6M | -$43.4M |
| Total assets | $78.3M | $89.3M | $115.7M | $152.4M | $189.5M |
| Total liabilities | $26.4M | $38.7M | $45.2M | $69.3M | $33.0M |
| Shareholders' equity | $35.3M | $50.5M | $70.6M | $83.1M | $156.6M |
| Ratios | |||||
| Operating margin | -279.5% | -34835.4% | -131.0% | -903.1% | -711.2% |
| Net margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% |
| Return on assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% |
| Return on equity | -49.8% | -66.2% | -26.9% | -96.2% | -46.7% |
| Debt / equity | 0.03× | 0.01× | 0.19× | 0.17× | 0.02× |
| Current ratio | 3.07 | 2.30 | 3.61 | 2.71 | 6.24 |
| Revenue growth | 7332.8% | -99.4% | 94.9% | -8.7% | 1351.7% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 34,533 | $135,369 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.75 (distress)
- Working capital / assets 0.667
- Retained earnings / assets -4.201
- EBIT / assets -0.274
- Equity / liabilities 1.341
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001818838 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.